Die Rolle Der Biomarker in Serum, Liquor Und Parenchym im Rahmen Der Aneurysmatischen Subarachnoidalblutung: Verlauf Und Korrelation zu Therapie Und Outcome - bioSAB -
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Aneurysmal Subarachnoid Hemorrhage
- Sponsor
- RWTH Aachen University
- Enrollment
- 310
- Locations
- 1
- Primary Endpoint
- Biomarker in serum, cerebrospinal fluid and parenchyma after aneurysmal SAH
- Last Updated
- 6 years ago
Overview
Brief Summary
The aim of this study is to improve the usability of biomarkers for the timely prediction of new complications following a cerebral hemorrhage, especially in combination with invasive, functional and local measurements for patients with aneurysmal subarachnoid hemorrhage (SAH). Based on analyzed biomarker profiles the chosen therapy efforts are assessed in their immediate and longer-term effectiveness.
Investigators
Walid Albanna
Priv.-Doz. Dr. med. Walid Albanna
RWTH Aachen University
Eligibility Criteria
Inclusion Criteria
- •male or female, age ≥ 18 years
- •signed consent for participation in the study
- •signed consent for further analysis of the samples collected during the clinical routine
- •in-patients
Exclusion Criteria
- •female or male patient \<18 years
- •pregnancy, lactation
- •lack of signed informed consent for participation in the study
- •lack of signed consent for the further analysis of the samples collected during the clinical routine
- •taking a study drug within the last thirty days
- •Simultaneous participation in another clinical trial (except participation as control group)
- •persons who are in a dependent relationship or employment with the sponsor or investigator
- •persons housed for a judicial or administrative order in an institution
Outcomes
Primary Outcomes
Biomarker in serum, cerebrospinal fluid and parenchyma after aneurysmal SAH
Time Frame: Each participant will be followed at hospital stay for an expected average of 3 weeks. The outcome measure will be assessed after 24 month.
Temporal development of alternative biomarkers in serum, cerebrospinal fluid and parenchyma after aneurysmal SAH, and their response as influenced by the treatment path.
Secondary Outcomes
- Clinical outcome(Each participant will be followed at hospital stay for an expected average of 3 weeks. The outcome measure will be assessed after 24 month)
- Image morphological outcome(Each participant will be followed at hospital stay for an expected average of 3 weeks. The outcome measure will be assessed after 24 month)